Last update 12 Dec 2024
SC-10914
Last update 12 Dec 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms S410914, SC 10914, SC10914 |
Target |
Mechanism PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Login to view timeline
Related
9
Clinical Trials associated with SC-10914SC10914 Monotherapy for gBRCA1/2 Mutation Advanced Ovarian Cancer Patients With at Least 2 Prior Lines of Chemotherapy: a Single Arm, Open Label, Multicenter Clinical Trial
SC10914单药治疗经2线或更多线化疗治疗失败的生殖系BRCA突变晚期卵巢癌的单臂、开放、多中心临床试验
[Translation] A single-arm, open-label, multicenter clinical trial of SC10914 monotherapy in patients with germline BRCA-mutated advanced ovarian cancer who have failed 2 or more lines of chemotherapy
食物对SC10914 药代动力学影响的Ⅰ期临床研究
[Translation] Phase I clinical study on the effect of food on the pharmacokinetics of SC10914
100 Clinical Results associated with SC-10914
Login to view more data
100 Translational Medicine associated with SC-10914
Login to view more data
100 Patents (Medical) associated with SC-10914
Login to view more data
100 Deals associated with SC-10914
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Ovarian Cancer | Phase 2 | CN | 24 Nov 2020 | |
| Ovarian Cancer | Phase 2 | CN | 24 Nov 2020 | |
| Locally advanced breast cancer | Phase 2 | CN | 12 Aug 2020 | |
| Metastatic breast cancer | Phase 2 | CN | 12 Aug 2020 | |
| Neoplasm Metastasis | Phase 2 | CN | 12 Aug 2020 | |
| BRCA mutation positive Breast Cancer | Phase 2 | CN | 01 Jul 2020 | |
| BRCA mutation positive Breast Cancer | Phase 2 | CN | 01 Jul 2020 | |
| Metastatic castration-resistant prostate cancer | Phase 2 | CN | 15 Jun 2020 | |
| Metastatic castration-resistant prostate cancer | Phase 2 | CN | 15 Jun 2020 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | CN | 01 Oct 2016 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT02940132 (ASCO2020) Manual  | Phase 1 | HR-positive/HER2-low Solid Tumors BRCA Mutation (germline) | 52 | jqwxevfmux(wpxtzqdvdk) = stcpkdagan atjmyhjzyf (xojczxqeiy ) View more | Positive | 29 May 2020 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free